Kanya Rajangam

Directeur Médical

Nkarta, Inc.Senti Biosciences, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€5,111

Latest filing published 11 Mar 2026 for Senti Biosciences, Inc.. Read the official filing

Filing timeline

BuySale

Kanya Rajangam

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Kanya Rajangam: trading record in brief

Kanya Rajangam, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Senti Biosciences Holdings, Inc. and Nkarta, Inc. Over a trading history stretching from 5 August 2021 to 9 March 2026, the count stands at 8 filings.

No open-market purchase appears, only 1 sale worth €5,111. Outside the open market, there are 5 share grants and 1 option exercise.

On 11 March 2026 came the latest disclosure, a share grant in Senti Biosciences Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.